CHRISTOPHER C MOORE

Summary

Affiliation: University of Virginia
Country: USA

Publications

  1. ncbi Point-of-care lactate testing predicts mortality of severe sepsis in a predominantly HIV type 1-infected patient population in Uganda
    CHRISTOPHER C MOORE
    Department of Internal Medicine, Division of Infectious Diseases and International Health, University of Virginia Health System, Charlottesville, VA 22908, USA
    Clin Infect Dis 46:215-22. 2008
  2. ncbi Eukaryotic translation initiation factor 5A small interference RNA-liposome complexes reduce inflammation and increase survival in murine models of severe sepsis and acute lung injury
    CHRISTOPHER C MOORE
    Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia Health System, Charlottesville, VA 22908, USA
    J Infect Dis 198:1407-14. 2008
  3. ncbi An A2A adenosine receptor agonist, ATL313, reduces inflammation and improves survival in murine sepsis models
    CHRISTOPHER C MOORE
    Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia, Box 801342, Charlottesville, VA 22908, USA
    BMC Infect Dis 8:141. 2008
  4. ncbi Treatment of severe sepsis with artemether-lumefantrine is associated with decreased mortality in Ugandan patients without malaria
    CHRISTOPHER C MOORE
    Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia, Charlottesville, Virginia 22908, USA
    Am J Trop Med Hyg 80:723-8. 2009
  5. ncbi Adrenal suppression due to an interaction between ritonavir and injected triamcinolone: a case report
    Kathryn Dort
    Department of Medicine, Division of Infectious Diseases and International Health, University of Virginia School of Medicine, Charlottesville, Virginia, USA
    AIDS Res Ther 6:10. 2009
  6. ncbi Severe sepsis in two Ugandan hospitals: a prospective observational study of management and outcomes in a predominantly HIV-1 infected population
    Shevin T Jacob
    Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA
    PLoS ONE 4:e7782. 2009

Research Grants

  1. The effects of A2A adenosine receptor agonists in sepsis
    Christopher Moore; Fiscal Year: 2007

Detail Information

Publications6

  1. ncbi Point-of-care lactate testing predicts mortality of severe sepsis in a predominantly HIV type 1-infected patient population in Uganda
    CHRISTOPHER C MOORE
    Department of Internal Medicine, Division of Infectious Diseases and International Health, University of Virginia Health System, Charlottesville, VA 22908, USA
    Clin Infect Dis 46:215-22. 2008
    ..Therefore, we evaluated the ability of a hand-held portable whole-blood lactate (PWBL) analyzer to predict mortality of patients who are admitted to the hospital with severe sepsis...
  2. ncbi Eukaryotic translation initiation factor 5A small interference RNA-liposome complexes reduce inflammation and increase survival in murine models of severe sepsis and acute lung injury
    CHRISTOPHER C MOORE
    Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia Health System, Charlottesville, VA 22908, USA
    J Infect Dis 198:1407-14. 2008
    ..Eukaryotic translation initiation factor 5A (eIF5A) is a regulator of apoptosis as well as inflammatory cell activation, making it a potential target for sepsis therapy...
  3. ncbi An A2A adenosine receptor agonist, ATL313, reduces inflammation and improves survival in murine sepsis models
    CHRISTOPHER C MOORE
    Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia, Box 801342, Charlottesville, VA 22908, USA
    BMC Infect Dis 8:141. 2008
    ..Here we describe molecular and cellular responses, as well as survival, in A 2A adenosine receptor (AR) agonist treated and untreated animals during experimental sepsis...
  4. ncbi Treatment of severe sepsis with artemether-lumefantrine is associated with decreased mortality in Ugandan patients without malaria
    CHRISTOPHER C MOORE
    Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia, Charlottesville, Virginia 22908, USA
    Am J Trop Med Hyg 80:723-8. 2009
    ..7%, SE = 15.2 versus 58.3%, SE = 3.7; Log rank chi(2) 3.94, P = 0.041). Research into the properties of A-L is needed to improve treatment of sepsis without compromising malarial susceptibility...
  5. ncbi Adrenal suppression due to an interaction between ritonavir and injected triamcinolone: a case report
    Kathryn Dort
    Department of Medicine, Division of Infectious Diseases and International Health, University of Virginia School of Medicine, Charlottesville, Virginia, USA
    AIDS Res Ther 6:10. 2009
    ..Practitioners of HIV medicine should be aware of the potential negative interaction of injected triamcinolone and ritonavir...
  6. ncbi Severe sepsis in two Ugandan hospitals: a prospective observational study of management and outcomes in a predominantly HIV-1 infected population
    Shevin T Jacob
    Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA
    PLoS ONE 4:e7782. 2009
    ..We conducted a prospective observational study reporting the management and outcomes of severely septic patients in two Ugandan hospitals. We describe their epidemiology, management, and clinical correlates for mortality...

Research Grants2

  1. The effects of A2A adenosine receptor agonists in sepsis
    Christopher Moore; Fiscal Year: 2007
    ..e., endotoxemia. These aims are proposed to identify crucial components in sepsis pathophysiology and characterize what is potentially a useful tool in the therapeutic arsenal used to combat sepsis. ..